
    
      The duration of the study per participant was to be at least 36 months, of which the
      treatment period was 18 months for all participants, followed by at least 18 months follow-up
      period.

      Participants received study treatment for up to 18 months from the time of study therapy
      initiation or less if one of the following occurred: disease progression, unacceptable
      toxicity, death, participant refusal or treatment delay beyond the time frame that is
      permitted for each treatment.
    
  